• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of the Canadian Academy of Child and Adolescent Psychiatry >Evaluation of the Effectiveness and Safety of Olanzapine as an Adjunctive Treatment for Anorexia Nervosa in Adolescents: An Open-Label Trial
【24h】

Evaluation of the Effectiveness and Safety of Olanzapine as an Adjunctive Treatment for Anorexia Nervosa in Adolescents: An Open-Label Trial

机译：评价奥氮平作为青少年神经性厌食症的辅助治疗的有效性和安全性：一项开放标签试验

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objectives To evaluate the effectiveness and safety of adjunctive olanzapine treatment for low weight adolescents with anorexia nervosa (AN). Methods A non-randomized open-label trial was conducted between 2010 and 2014. Participants received standard treatment and were invited to take olanzapine at study enrollment. Participants could accept, continue, or discontinue olanzapine as treatment progressed. Weight and psychological outcomes were monitored. Results Of 239 adolescents assessed, 65 met inclusion criteria, 38 enrolled in the study, and 32 were retained for analysis. Twenty-two participants took olanzapine ( medication group ) and ten participants did not ( comparison group ). Participants in the medication group demonstrated a higher rate of weight gain compared to those who did not receive olanzapine ( p = .012). No serious adverse events were noted, although seven participants (31.8%) discontinued olanzapine due to a side effect. Conclusion Preliminary results suggest that olanzapine may help facilitate weight gain in adolescents with AN. The importance of medical monitoring over the course of treatment is discussed. Evaluation of the Efficacy and Safety of Olanzapine for Anorexia Nervosa in Children and Adolescents; http://clinicaltrials.gov ; {"type":"clinical-trial","attrs":{"text":"NCT01184443","term_id":"NCT01184443"}} NCT01184443 .
机译：目的评估奥氮平辅助治疗对神经性厌食症（AN）的低体重青少年的有效性和安全性。方法在2010年至2014年之间进行了一项非随机开放标签试验。参与者接受了标准治疗，并被邀请参加研究时服用奥氮平。随着治疗的进展，参与者可以接受，继续或终止奥氮平。监测体重和心理结局。结果对239名青少年进行了评估，其中65名符合入选标准，其中38名入选了该研究，还有32名被保留用于分析。 22名参与者服用了奥氮平（药物治疗组），而十名参与者没有服用（比较组）。与未接受奥氮平治疗的患者相比，药物治疗组的患者显示出更高的体重增加率（p = 0.012）。尽管有七名参与者（31.8％）由于副作用停用奥氮平，但未发现严重不良事件。结论初步结果表明，奥氮平可能有助于促进AN青少年的体重增加。讨论了在治疗过程中医学监测的重要性。奥氮平对儿童和青少年神经性厌食症的疗效和安全性评估; http://clinicaltrials.gov; {“ type”：“临床试验”，“ attrs”：{“ text”：“ NCT01184443”，“ term_id”：“ NCT01184443”}} NCT01184443。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号